Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its Logix Smart™ SARS-CoV-2 2-Gene multiplex test has been validated by the UK Health Security Agency under the CTDA, allowing it to be marketed in the UK. This test can utilize various sample types, including saliva. CEO Dwight Egan emphasized that this approval reflects the high standards of the company's testing technology and its commitment to providing reliable COVID-19 testing solutions globally. The test is available for purchase through Client Life Science, the authorized distributor in the UK.
Co-Diagnostics, Inc. (NASDAQ: CODX) will announce its third quarter 2021 financial results on November 11, 2021, post-market close. A conference call and webcast will occur at 4:30 p.m. EDT the same day to discuss these results, featuring CEO Dwight Egan, CFO Brian Brown, and Andrew Benson from Investor Relations. The company's diagnostics technology focuses on the detection of DNA and RNA molecules and is utilized across various industries.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics Pvt Ltd, received approval from India's CDSCO to manufacture and sell the Saragene™ Dengue and Chikungunya Multiplex RT-PCR test as an in vitro diagnostic. This milestone is significant as it represents the 10th assay approved by the CDSCO for CoSara. The multiplex test enhances the company's portfolio designed to address public health needs in India, where dengue and chikungunya pose significant health risks. The approval reflects the company's commitment to innovation in molecular diagnostics.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced the introduction of its at-home and point-of-care PCR device at the 2021 AACC Annual Scientific Meeting in Atlanta, GA, from September 26-30. The press conference is scheduled for September 28 at 1:00 PM ET, where details on the PCR Platform and other updates will be shared. Co-Diagnostics will also showcase its diagnostic products at booth #2454. Notably, the new device has not yet been reviewed by the U.S. FDA and is not currently available for sale.
Co-Diagnostics (Nasdaq: CODX) announced a corporate rebranding following significant growth, aiming to reflect its expanded mission and entry into new diagnostics sectors. The company, known for its Logix Smart™ COVID-19 Test, has successfully sold over 22 million tests globally. They are developing an innovative at-home and point-of-care PCR testing platform that promises rapid results. The rebranding includes a new logo and marketing materials, anticipated to launch as they optimize their new device for FDA review. This change aims to enhance broad access to quality diagnostic solutions.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present at the 5th Advances in Circulating Tumor Cells (ACTC) conference in Kalamata, Greece, from September 22-25, 2021. The presentation is scheduled for September 23 at 14:50 local time. The Company's Logix Smart™ COVID-19 Tests will be used for on-site testing of attendees, highlighting its expanding presence in Europe. Co-Diagnostics aims to engage with both new and existing customers to showcase its diagnostic products. Interested European distributors and laboratories can contact the Company for more information.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced that its Logix Smart™ Influenza A/Influenza B/COVID-19 "ABC" Test has been approved for sale in Mexico by the Mexican Department of Epidemiology (InDRE). This clearance follows a successful independent evaluation of the test's sensitivity and specificity. Following the CE marking, demand has surged for the ABC multiplex diagnostic, particularly as flu season approaches amidst reduced immunity predictions. The company views this approval as validation of its CoPrimer™ platform and a step toward enhancing access to affordable diagnostics.
Co-Diagnostics, Inc. (NASDAQ: CODX) will present at the Sidoti Fall Virtual Investor Conference on September 23, 2021, at 3:15 p.m. EDT. The presentation will be led by CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Investors can access the event through the Co-Diagnostics website. Registration for the presentation and one-on-one meetings is available at www.sidoti.com/events.
Co-Diagnostics (Nasdaq: CODX) announced that its joint venture, CoSara Diagnostics, received clearance from India's CDSCO to manufacture and sell Saragene™ dengue and chikungunya RT-PCR tests as in vitro diagnostics. Utilizing Co-Diagnostics' patented CoPrimer™ technology, these tests aim to accurately detect these mosquito-borne viruses, addressing a significant public health issue as the incidence of dengue has dramatically increased globally. CEO Dwight Egan emphasized the importance of accurate diagnosis for effective treatment and highlighted CoSara's prior approvals for various tests in India.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced today that CEO Dwight Egan will join a panel discussion titled "How We Can Defeat the Next Pandemic," hosted by Scott Gottlieb, M.D., at the H.C. Wainwright & Co. 2021 Global Investor Conference. This virtual event is scheduled for September 15, 2021, at 12:00 pm ET. Attendees can register for the conference here. Additionally, Mr. Egan and CFO Brian Brown will present a Healthcare & Biotech On-Demand session available starting September 13, 2021, at 7:00 am ET on their website.